This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Despite major therapeutic progress, most advanced solid tumors are still incurable. Cancer interception is the active way to combat cancer onset, and development of this approach within high-risk populations seems a logical first step. Until now, strategies for the identification of high-risk subjects have been based on low-sensitivity and low-specificity assays. However, new liquid biopsy assays, “the Rosetta Stone of the new biomedicine era,” with the ability to identify circulating biomarkers with unprecedented sensitivity, promise to revolutionize cancer management. This review focuses on novel liquid biopsy approaches and the applications to cancer interception. Cancer interception involves the identification of biomarkers associated with developing cancer, and includes genetic and epigenetic alterations, as well as circulating tumor cells and circulating epithelial cells in individuals at risk, and the implementation of therapeutic strategies to prevent the beginning of cancer and to stop its development. Large prospective studies are needed to confirm the potential role of liquid biopsy for early detection of precancer lesions and tumors.
Footnotes
Cancer Discov 2020;10:1635–44
- Received April 12, 2020.
- Revision received June 22, 2020.
- Accepted August 5, 2020.
- Published first October 9, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
Volume 10, Issue 11
Jump to section
- Article
- Abstract
- Introduction
- From the Lens of COPD to Lung Cancer
- From Adenomatous Polyps to Colon Cancer
- The Special Case of ctDNA in CI and Early Detection
- Prevention, Early Detection, and the Challenges of Developing Treatments as Current Cancer Research Priorities
- Conclusions
- Disclosure of Potential Conflicts of Interest
- Footnotes
- References
- Figures & Data
- Info & Metrics